Muscle Weakness: Drugs That Cause It and Drugs That Treat It

Why Drug-Induced Muscle Weakness Is More Common Than You Think

Drug-induced myopathy is responsible for a large share of acquired muscle disease in clinical practice. A 2014 review in Cleveland Clinic Journal of Medicine estimated that medications account for the majority of toxic and acquired myopathies seen in referral centers [1]. The challenge: patients and prescribers often attribute new-onset weakness to aging, deconditioning, or stress rather than a pill that has been on board for months.

Recognizing drug-induced weakness matters because it is usually reversible. Once the offending agent is stopped or the dose is reduced, most patients recover full strength within weeks to a few months [1]. The list of causative agents is long. It includes lipid-lowering drugs, immune-suppressive agents, antimicrobials, antipsychotics, and several cardiovascular medications. Some drugs damage the muscle fiber directly (necrotizing myopathy), while others disrupt mitochondrial function or trigger an autoimmune inflammatory response [2].

A structured drug history is the single most useful diagnostic step when a patient presents with symmetric proximal weakness and an elevated creatine kinase (CK). The American College of Rheumatology's 2017 classification criteria for idiopathic inflammatory myopathies specifically require exclusion of drug-induced causes before assigning an autoimmune diagnosis [3].

Statins: The Most Discussed Cause of Medication-Related Weakness

Statin-associated muscle symptoms (SAMS) are the number-one reason patients discontinue lipid-lowering therapy. The exact prevalence is debated. Randomized controlled trials report myalgia rates of 1-5%, but observational registries and the STOMP trial (N=420) found that statin users had measurably higher CK levels and reduced muscle strength compared with placebo, even among those who did not report symptoms [4].

A more severe form, statin-associated autoimmune myopathy (SAAM), is rare but can be disabling. It is characterized by anti-HMGCR antibodies, CK levels often exceeding 10,000 U/L, and proximal weakness that does not resolve after drug discontinuation [5]. SAAM requires immunosuppressive therapy, typically methotrexate or intravenous immunoglobulin (IVIG).

For the much more common self-limited SAMS, the 2018 ACC/AHA cholesterol guideline recommends a "rechallenge" approach: stop the statin for 2-4 weeks, confirm symptom resolution, then restart at a lower dose or switch to a different statin [6]. Rosuvastatin and pitavastatin have lower rates of muscle complaints in head-to-head comparisons, and every-other-day dosing of rosuvastatin has shown acceptable LDL reduction with fewer muscle symptoms in a 2013 Annals of Internal Medicine analysis [7].

Corticosteroids and Steroid Myopathy

Chronic glucocorticoid use is the second most common drug cause of muscle weakness. Steroid myopathy presents as painless proximal weakness, particularly in the hip flexors and quadriceps. Fluorinated steroids (dexamethasone, triamcinolone) carry higher risk than non-fluorinated agents like prednisone, but any glucocorticoid given at ≥10 mg/day prednisone-equivalent for more than 4 weeks can trigger it [8].

CK is typically normal in steroid myopathy, which distinguishes it from inflammatory myopathies. Electromyography (EMG) may show myopathic motor unit potentials, but findings can be subtle. The diagnosis is largely clinical: a patient on chronic steroids develops progressive difficulty rising from a chair or climbing stairs, and strength improves when the dose is tapered [8].

A 2019 Cochrane review found no pharmacologic intervention that reliably prevents steroid myopathy [9]. The best evidence supports concurrent resistance exercise. A trial published in JAMA Internal Medicine showed that transplant patients on high-dose prednisone who performed supervised resistance training three times per week preserved significantly more quadriceps strength than sedentary controls over 12 weeks [10].

Fluoroquinolones, Colchicine, and Other Offenders

The U.S. Food and Drug Administration added a black-box warning to fluoroquinolone antibiotics in 2016 and expanded it in 2018, citing tendinopathy, peripheral neuropathy, and myopathy as serious risks [11]. Ciprofloxacin and levofloxacin are the most frequently implicated.

Colchicine causes a vacuolar myopathy that mimics polymyositis. Risk is dose-dependent and dramatically higher in patients with renal impairment who cannot clear the drug efficiently [1]. Hydroxychloroquine, widely used in rheumatology, can produce a slowly progressive myopathy with characteristic curvilinear body inclusions on biopsy. It typically appears after years of use and reverses over 6-12 months once the drug is stopped [2].

Other notable causes include:

• Amiodarone: can produce both a proximal myopathy and a peripheral neuropathy
• Zidovudine (AZT): mitochondrial myopathy with ragged red fibers on biopsy
• Immune checkpoint inhibitors (nivolumab, pembrolizumab): may trigger a severe necrotizing or inflammatory myositis, sometimes overlapping with myocarditis [12]
• D-penicillamine: can induce a myasthenia-like syndrome with detectable acetylcholine receptor antibodies

GLP-1 Receptor Agonists and Lean Mass Loss

Semaglutide and tirzepatide produce significant total body weight loss, but a portion of that loss is lean mass. In the STEP 1 trial (N=1,961), participants on semaglutide 2.4 mg lost 14.9% of body weight at 68 weeks versus 2.4% with placebo, and approximately 40% of the weight lost was lean tissue as measured by DEXA [13]. The SELECT trial (N=17,604) confirmed cardiovascular benefit but did not report lean mass outcomes at scale [14].

This lean-mass deficit can translate to functional weakness, especially in older adults. The Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy recommends concurrent resistance training and protein intake of ≥1.2 g/kg/day for patients over 65 starting GLP-1 therapy to mitigate sarcopenic risk [15]. Tirzepatide's SURMOUNT-1 data (N=2,539) showed a similar proportion of lean mass loss, though the absolute amount was larger given greater total weight reduction (22.5% of body weight at the highest dose) [16].

"Preserving muscle during GLP-1-mediated weight loss is not optional for older patients. It should be prescribed alongside the medication itself," noted the Endocrine Society guideline committee in their 2024 recommendation statement [15].

Drugs That Treat Muscle Weakness: Condition by Condition

The pharmacotherapy of muscle weakness depends entirely on the underlying diagnosis. Below are the major conditions and their evidence-based drug treatments.

Myasthenia Gravis

Pyridostigmine, an acetylcholinesterase inhibitor, remains the first-line symptomatic treatment. It does not alter disease progression but improves neuromuscular transmission within 30-60 minutes of dosing [17]. For patients with inadequate response, immunosuppression with prednisone plus a steroid-sparing agent (azathioprine, mycophenolate, or rituximab) is standard. A 2022 phase 3 trial published in The Lancet Neurology demonstrated that efgartigimod, a neonatal Fc receptor blocker, produced clinically meaningful improvement in 68% of AChR-antibody-positive patients versus 30% on placebo [18].

Inflammatory Myopathies (Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy)

High-dose prednisone (1 mg/kg/day, tapered over months) is the initial treatment. Methotrexate or azathioprine is added early as a steroid-sparing agent per the 2022 ACR/EULAR recommendations [3]. Refractory cases may respond to IVIG, which showed superiority over placebo in a landmark NEJM trial by Dalakas et al. for dermatomyositis [19]. Rituximab is increasingly used off-label based on the RIM trial data showing benefit in 83% of refractory patients at 44 weeks [20].

Spinal Muscular Atrophy

Three FDA-approved therapies have changed outcomes in this previously untreatable genetic condition. Nusinersen (Spinraza), an intrathecal antisense oligonucleotide, was approved in 2016 after the ENDEAR trial showed 51% of treated infants achieved motor milestones versus 0% on sham procedure [21]. Onasemnogene abeparvovec (Zolgensma), a one-time gene therapy, was approved in 2019 for children under 2. Risdiplam (Evrysdi), an oral SMN2 splicing modifier, was approved in 2020 for patients aged 2 months and older [22].

Hypogonadism-Associated Weakness

Testosterone deficiency produces measurable losses in muscle mass and strength. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies in men ≥65 with low testosterone, found that one year of transdermal testosterone increased lean mass by 1.25 kg (P<0.001) and improved stair-climbing power and 6-minute walk distance [23]. The 2018 Endocrine Society guideline recommends testosterone replacement for men with consistently low morning total testosterone (<300 ng/dL) plus symptoms including weakness, fatigue, or reduced physical performance [24].

Thyroid-Related Weakness

Both hypothyroidism and hyperthyroidism cause myopathy. Hypothyroid myopathy presents with proximal weakness, elevated CK, and slowed reflexes. It resolves with levothyroxine replacement. Hyperthyroid myopathy, more common in Graves disease, features proximal wasting and normal or mildly elevated CK. Treatment targets the thyroid excess (methimazole, radioiodine, or surgery) [25].

How Muscle Weakness Is Diagnosed

Diagnosis starts with the history. The pattern of weakness (proximal versus distal, symmetric versus asymmetric, acute versus chronic) narrows the differential dramatically. Proximal, symmetric weakness developing over weeks to months in a patient on a known offending medication points strongly to drug-induced myopathy.

Laboratory testing begins with serum CK. A CK level above five times the upper limit of normal in a weak patient almost always indicates a myopathy rather than a neuropathy [2]. Thyroid-stimulating hormone (TSH), comprehensive metabolic panel, and erythrocyte sedimentation rate (ESR) screen for common systemic causes.

"An elevated CK in the setting of new proximal weakness should trigger immediate medication review before ordering advanced testing," according to the American Academy of Neurology's 2016 practice parameter on evaluation of distal symmetric polyneuropathy, which also applies broadly to acquired myopathy workup [26].

Electrodiagnostic studies (nerve conduction studies and EMG) distinguish myopathic from neurogenic patterns. MRI of the affected muscle groups can reveal edema in inflammatory myopathies and fatty replacement in chronic disease. Muscle biopsy remains the gold standard for confirming histologic subtype, particularly when autoimmune or genetic etiologies are suspected [3].

Myasthenia-specific testing includes acetylcholine receptor antibodies (positive in ~85% of generalized MG), anti-MuSK antibodies, and repetitive nerve stimulation showing a decremental response [17].

When to Seek Urgent Evaluation

Most drug-induced muscle weakness develops gradually and resolves with medication adjustment. But certain red flags demand same-day or emergency evaluation:

• Rapidly progressive weakness over days, especially ascending from legs to arms (suggests Guillain-Barré syndrome)
• Respiratory muscle involvement: dyspnea at rest, orthopnea, or inability to count to 20 in one breath
• Dysphagia or dysarthria with weakness (myasthenic crisis or bulbar-onset ALS)
• CK above 10,000 U/L with dark urine (rhabdomyolysis risk with potential acute kidney injury)
• Concurrent myocarditis symptoms (chest pain, arrhythmia) in a patient on immune checkpoint inhibitors [12]

A 2020 BMJ clinical review reported that delayed recognition of immune checkpoint inhibitor-related myositis carried a mortality rate exceeding 20%, compared with <5% when identified and treated within the first week of symptom onset [12].

Prevention and Monitoring Strategies

For patients starting high-risk medications, baseline CK measurement provides a reference point. The National Lipid Association recommends baseline CK before initiating statin therapy in patients with pre-existing muscle complaints, hypothyroidism, or renal impairment [6].

Practical monitoring steps include:

• Statins: ask about muscle symptoms at every follow-up; check CK only if symptoms develop
• Corticosteroids: assess proximal strength (timed chair rise) at each visit when prednisone ≥10 mg/day for more than 4 weeks
• Checkpoint inhibitors: measure CK and troponin at baseline and with each infusion cycle for the first 3-4 months
• Colchicine: monitor renal function and reduce dose when eGFR falls below 30 mL/min/1.73 m²

Resistance exercise is the single intervention with evidence across multiple drug-induced myopathy subtypes. A 2021 meta-analysis of 14 RCTs (N=832) in Medicine & Science in Sports & Exercise found that structured resistance training improved knee extensor strength by a mean of 13.4% in patients with inflammatory myopathies, with no increase in disease flares [27].

Patients on GLP-1 agonists should target 2-3 sessions per week of progressive resistance training and maintain protein intake at 1.2-1.6 g/kg/day, particularly if over age 60 [15].